1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. GLOBAL BIOBETTERS MARKET BY TYPE
5.1. Introduction
5.2. Monoclonal Antibodies (mAbs)
5.3. Vaccines
5.4. Recombinant Proteins
5.5. Antibody–Drug Conjugates (ADCs)
5.6. Others
6. GLOBAL BIOBETTERS MARKET BY APPLICATION
6.1. Introduction
6.2. Oncology
6.3. Neurology
6.4. Nephrology
6.5. Autoimmune & Inflammatory Diseases
6.6. Infectious Diseases
6.7. Others
7. GLOBAL BIOBETTERS MARKET BY END-USER
7.1. Introduction
7.2. Biopharmaceutical Companies
7.3. Contract Research Organizations (CROs)
7.4. Academic & Research Institutes
8. GLOBAL BIOBETTERS MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. By Type
8.2.2. By Application
8.2.3. By End-User
8.2.4. By Country
8.2.4.1. USA
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. By Type
8.3.2. By Application
8.3.3. By End-User
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. By Type
8.4.2. By Application
8.4.3. By End-User
8.4.4. By Country
8.4.4.1. United Kingdom
8.4.4.2. Germany
8.4.4.3. France
8.4.4.4. Spain
8.4.4.5. Others
8.5. Middle East and Africa
8.5.1. By Type
8.5.2. By Application
8.5.3. By End-User
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.2. UAE
8.5.4.3. Others
8.6. Asia Pacific
8.6.1. By Type
8.6.2. By Application
8.6.3. By End-User
8.6.4. By Country
8.6.4.1. China
8.6.4.2. Japan
8.6.4.3. India
8.6.4.4. South Korea
8.6.4.5. Taiwan
8.6.4.6. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Celltrion
10.2. GC Pharma
10.3. Ildong Pharmaceutical Co., Ltd.
10.4. Samsung Bioepis
10.5. Amgen Inc.
10.6. Novartis AG
10.7. Galil-Ofek
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES